Ironwood Pharmaceuticals, Inc. (IRWD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 6.06 |
| Open | 6.12 |
| Bid | 5.91 x 400 |
| Ask | 5.97 x 400 |
| Day's Range | 5.85 - 6.13 |
| 52 Week Range | 5.85 - 15.70 |
| Volume | |
| Avg. Volume | 4,387,803 |
| Market Cap | 945.794M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.78 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.83 |
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
- GuruFocus.com
Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements
Revenue Falls Short of Expectations While Clinical Trials Show Promising Outcomes
© 2024 Yahoo. All rights reserved.